← The Wire·Consumer·

Labcorp to offer FDA-cleared Alzheimer's blood test for primary and specialty care

Labcorp will offer the first FDA-cleared single-biomarker blood test that can both rule in and rule out amyloid pathology associated with Alzheimer’s disease in primary and specialty care. The test expands Labcorp’s diagnostic reach into a large unmet-care pathway, but the commercial contribution and rollout economics are not yet disclosed.

PR NEWSWIRE / FILE

The story

The Elecsys pTau-217 test measures phosphorylated Tau 217, a biomarker associated with amyloid pathology and Alzheimer's disease. Labcorp said the test is FDA-cleared for use across specialty and primary care settings, distinguishing it from tests limited to narrower clinical environments.

The product connects Labcorp with Roche's Elecsys diagnostic platform and with clinicians evaluating patients for possible Alzheimer's disease. Its ability to rule in and rule out amyloid pathology could allow blood testing to serve as an earlier screening step before more specialized workups.

Our read · Mon, Aug 24

The FDA-cleared Alzheimer’s blood test adds a differentiated growth option for LH, though the near-term earnings read remains unquantified.

Why. The product gives LH a regulatory-backed offering that can broaden testing beyond specialty-care channels, adding a potential growth vector to a business that reported $14.0B of revenue and 7.2% YoY growth in FY 2025. The trade is constructive but measured because the announcement supplies no pricing, volume, reimbursement, or revenue forecast to support a larger immediate repricing.

Both cases

The case it holdsFDA clearance across primary and specialty care, combined with LH’s existing diagnostic distribution, provides a concrete path for the test to become a scalable Alzheimer’s screening product.
The case it breaksLimited near-term bear case from the announcement itself, but the financial impact remains unproven because no pricing, reimbursement, volume, or revenue contribution was disclosed.

What could change this view: The setup fails if primary-care adoption, reimbursement, or test volume develops slowly and the product produces little incremental revenue relative to LH’s $14.0B base.

Labcorp Holdings stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by PR Newswire as Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →